Thyroglobulin Doubling Time Calculator
Thyroglobulin Doubling Time Calculator
Estimate the thyroglobulin doubling time in differentiated thyroid cancer surveillance from two values and the interval between them — and see why a falling result is the good one.
Thyroglobulin Doubling Time
Two Tg values over timeThyroglobulin 0.8 ng/mL rising to 2.4 ng/mL over 12 months, on the same assay, with a negative thyroglobulin antibody on both samples
Formula
- Tg₁, Tg₂
- the earlier and later thyroglobulin values, ng/mL, from the same assay in the same laboratory
- months
- the interval between the two samples
- ln(2)
- 0.693 — the natural-log constant for exponential doubling
- a negative result
- means thyroglobulin fell over the interval, so no doubling is occurring. That is the good outcome, and this page reports it as one rather than as an error
- two values or four
- the prognostic figures below were derived by regression on four or more values. A two-point estimate is a screening approximation and no more
- anti-Tg antibody
- must be negative on both samples. A positive antibody does not slow the doubling time — it invalidates the measurement the doubling time is made of
Worked example
Thyroglobulin 0.8 ng/mL rising to 2.4 ng/mL over 12 months, on the same assay, with a negative thyroglobulin antibody on both samples
Tg₂ ÷ Tg₁ = 2.4 ÷ 0.8 = 3.00 — thyroglobulin tripled over the interval
ln(3.00) = 1.0986, and ln(2) = 0.6931
12 × 0.6931 ÷ 1.0986 = 7.6 months, which is 0.63 years
Under 12 months → the group in which Miyauchi reported a ten-year cause-specific survival of 50%
The velocity is (2.4 − 0.8) ÷ 12 = 0.133 ng/mL per month, which is a useful sanity check: a doubling time is a ratio and says nothing about the absolute amount
Both values were on the same assay and the antibody was negative, so the figure is interpretable at all
Doubling time and ten-year cause-specific survival
| Thyroglobulin doubling time | 10-year cause-specific survival | Reading |
|---|---|---|
| Negative (thyroglobulin falling) | 100% | No doubling. The reassuring result |
| Under 1 year | 50% | The strongest adverse signal in the series, and an independent predictor on multivariate analysis |
| 1 – 3 years | 95% | Intermediate; interpret with the absolute value and the imaging |
| 3 years or more | 100% | Effectively indistinguishable from a falling thyroglobulin |
Four things that make a thyroglobulin doubling time uninterpretable
| Problem | Why it matters |
|---|---|
| A positive thyroglobulin antibody | Not a caveat — a disqualification. In immunometric assays the antibody blocks the epitopes the method depends on and thyroglobulin reads falsely low, so both values are wrong by an unknown and non-constant amount. Miyauchi’s cohort excluded these patients. See the anti-Tg antibody page for the mechanism and the workaround |
| A change of assay between the two samples | Results are not transferable between methods even after standardisation to a common reference material. The meta-analysis is explicit: “if the same assays are used in individual patients, the Tg-DT values remain comparable” — the converse is the warning. See the thyroglobulin page |
| Only two values | The prognostic figures come from regression on four or more measurements. Two points cannot distinguish a trend from a pair of outliers, and values near the assay’s functional sensitivity are where the noise is worst |
| A changed TSH between the samples | Thyroglobulin release is TSH-driven. A stimulated value and a suppressed value are not two points on one curve, and a change in the degree of suppression will move thyroglobulin without any change in tumour burden |
The same arithmetic on three analytes
| Thyroglobulin | PSA | hCG | |
|---|---|---|---|
| Interval measured in | Months | Months | Hours |
| Concerning result | Under 1 year | Under 3 months (very high risk) | Slower than 48–72 hours |
| Direction of concern | Fast doubling is bad | Fast doubling is bad | Slow doubling is bad |
| Main interference | Anti-Tg antibody — invalidates the result entirely | Prostatitis, recent instrumentation | Rate naturally slows above about 6,000–10,000 IU/L |
| On this site | This page | PSA doubling time | hCG doubling time |
The antibody question comes first, and a falling thyroglobulin is the good answer
After total thyroidectomy and remnant ablation for differentiated thyroid cancer there should be no source of thyroglobulin left, so any measurable concentration reflects residual or recurrent disease, and the rate at which it changes matters more than any single value. The arithmetic is exponential and the same as for any other doubling time: the interval multiplied by the natural logarithm of two, divided by the natural logarithm of the ratio of the two values. The threshold in circulation is one year, and it has a primary source rather than being a rule of thumb. Miyauchi and colleagues followed 426 patients with four or more thyroglobulin measurements after total thyroidectomy and reported ten-year cause-specific survival of 50% where the doubling time was under a year, 95% at one to three years, and 100% both at three years or more and where thyroglobulin was falling. The doubling time “remained the only independent predictor by multivariate analysis” for death, distant metastasis and loco-regional recurrence. A 2022 meta-analysis of eleven studies and 1,421 patients put the risk ratio for recurrence or progression with a doubling time under one year at 2.09, with a confidence interval of 1.49 to 2.94.
Before any of that applies, one question has to be answered: is the thyroglobulin antibody negative? This is what makes thyroglobulin different from PSA, where the arithmetic on this page is otherwise identical. A positive anti-thyroglobulin antibody does not add noise to the measurement — in the immunometric assays most laboratories run it blocks the epitopes the method depends on and the thyroglobulin is reported falsely low, by an amount that is neither known nor constant. Two falsely low values produce a doubling time that is arithmetically impeccable and clinically meaningless, and it will usually look reassuring. Miyauchi’s cohort was restricted to patients with an undetectable antibody for exactly this reason, so the survival figures above simply do not apply to an antibody-positive patient. The anti-Tg antibody page covers the mechanism, the prevalence and the mass-spectrometry workaround, and the thyroglobulin page covers the assay standardisation problem; neither is repeated here. What this page adds is the consequence for this particular calculation, which is that a doubling time from antibody-positive samples is not a slow doubling time — it is no measurement at all.
Two more conditions on the inputs. Both values must come from the same assay: standardisation against a common reference preparation has narrowed the differences between methods without abolishing them, and the meta-analysis puts the rule the right way round — “if the same assays are used in individual patients, the Tg-DT values remain comparable”. A laboratory changing platform mid-surveillance can manufacture an apparent doubling. And both values should come from a comparable degree of TSH suppression, because thyroglobulin release is TSH-driven; a stimulated value and a suppressed value are not two points on the same curve. Worth noting here that the 2025 ATA differentiated thyroid cancer guideline no longer gives numeric TSH suppression targets at all, stating only that TSH should be kept below or within the reference range, so the degree of suppression is now more variable between patients than it used to be — one more reason to check that the two samples are comparable rather than assuming it.
Finally, the two results people mistake for errors. A negative doubling time means the second value was lower than the first, so nothing is doubling; that is the outcome with 100% ten-year cause-specific survival in the source cohort, and this page gives it its own verdict rather than discarding it. A very large doubling time means the two values were nearly identical, which near the assay’s functional sensitivity is often analytical variation rather than biology — a thyroglobulin moving from 0.21 to 0.22 ng/mL will generate a doubling time of decades and should not be reported as a measurement. And two identical values produce no answer at all, because the logarithm of one is zero. Most importantly, the prognostic figures quoted above were derived from four or more measurements regressed over time. Two values give a screening estimate; the decision belongs with the trend, the absolute concentration, the imaging and the treating team. This supports a clinician’s judgement rather than replacing it. It is arithmetic on the figures entered, and it knows nothing about the patient in front of you.
Frequently asked questions
What thyroglobulin doubling time is concerning?
Under one year. Miyauchi et al reported ten-year cause-specific survival of 50% in that group against 95% at one to three years and 100% at three years or more, and the doubling time was the only independent predictor of death, distant metastasis and recurrence on multivariate analysis. A 2022 meta-analysis put the risk ratio for recurrence or progression below one year at 2.09 (1.49–2.94).
Why does my result show a negative number?
Because the second thyroglobulin was lower than the first, so there is no doubling to time. That is the reassuring result: patients with a negative doubling time in the derivation cohort had a ten-year cause-specific survival of 100%, the same as those doubling more slowly than three years.
Can a thyroglobulin doubling time be used if the anti-Tg antibody is positive?
No. In immunometric assays a positive thyroglobulin antibody blocks the epitopes the method relies on and thyroglobulin reads falsely low by an unknown and inconsistent amount, so both values are wrong and the doubling time is meaningless — usually in the reassuring direction. The derivation cohort was restricted to patients with an undetectable antibody.
Do both thyroglobulin values need to come from the same assay?
Yes. Results are not transferable between methods even after standardisation to a common reference preparation. The 2022 meta-analysis states that “if the same assays are used in individual patients, the Tg-DT values remain comparable” — a platform change between the two samples can manufacture an apparent doubling.
How many thyroglobulin values are needed for a reliable doubling time?
Four or more. The published prognostic figures were derived by regression on at least four measurements; a two-point calculation like this one is a screening estimate, and it is least reliable exactly where surveillance values usually sit — close to the assay’s functional sensitivity.
Related calculators
References
- Miyauchi A, Kudo T, Miya A, et al. Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy. Thyroid. 2011. doi:10.1089/thy.2010.0355 (PMID 21649472).
- The role of thyroglobulin doubling time in differentiated thyroid cancer: a meta-analysis. Endocr Connect. 2022;11(4):e210648 (PROSPERO CRD42021257947) — author list not shown by the source consulted and therefore not reproduced here.
- Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1–133 — response-to-therapy definitions and the place of a rising anti-Tg antibody in them.
- American Thyroid Association, Clinical Thyroidology for the Public (March 2026), on the 2025 ATA differentiated thyroid cancer guidelines: “the current guidelines do not provide target TSH ranges for any patients, but simply state that TSH should be maintained ‘below’ or ‘within’ the reference range”.
Medical Disclaimer: The tools and content provided here are for educational and reference purposes only. They are not intended to substitute for professional medical advice, diagnosis, or treatment. Clinical decisions should always be based on the comprehensive assessment of a qualified healthcare professional.